Interleukin 17A (IL-17A)

Where the papers sit

20 papers from the last 6 months study Interleukin 17A (IL-17A) directly · updated from PubMed 12 Oct 2026

• IL-17A Inflammation and Immunotherapy

  IL-17A targeting is moving from inflammatory disease mechanisms toward cancer treatment and biomarker-guided intervention. PTGS2/NLRP3 activation, IL-6, STAT3/NF-κB signaling and endothelial activation recur across leukemia, rhinitis and cancer-associated thrombosis. Anti-IL-17A strategies are paired with anti-CD73, GLP-1R agonism or checkpoint blockade, including melanoma brain metastases. T-cell exhaustion, adaptive IL-17A sources and humoral immunity remain important determinants of response.

  7 papers · 35%

• Bimekizumab in Psoriasis

  Bimekizumab is being assessed for durable plaque-psoriasis control, including patients previously exposed to biologics and those with palmoplantar disease. Real-world studies emphasize effectiveness, safety and drug survival over two years. Dual IL-17A/IL-17F blockade is the recurring therapeutic rationale, while genistein-mediated NF-κB inhibition offers a separate preclinical anti-inflammatory approach. Evidence outside psoriasis remains limited to isolated reports, including IgA nephropathy.

  4 papers · 20%

• IL-17A in Vasculitis

  Secukinumab is being tested as an IL-17A-directed option for polymyalgia rheumatica and giant cell arteritis. The clinical question is whether it can control disease while reducing glucocorticoid exposure and its infection risk. Trial evidence in polymyalgia rheumatica is more developed than the broader vasculitis application. Sex-specific regulation of IL-17A adds a mechanistic dimension but leaves treatment implications unresolved.

  3 papers · 15%

• Others — Diverse IL-17A Biology

  IL-17A appears across toxicogenomics, vaccination, ischemia, ocular disease, parasitic infection and bladder cancer. The studies examine inflammatory signaling, immune responses and possible therapeutic or preventive roles. Computational epitope discovery and cytokine-axis analysis recur, but no single disease mechanism or treatment direction unifies the set. Its common ground is broad exploration of IL-17A-associated biology.

  6 papers · 30%